Program
Ranolazine
Also written as “Test formulation (Ranolazine extended-release tablets)”, “Reference formulation (Ranolazine extended-release tablets)” and “Ranolazine 500 mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Angina Pectoris · Atrial Fibrillation · Coronary Artery Disease · Cardiovascular Diseases, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 180 open or running | phase 4since Mar 24, 2008 | Sep 8, 2004 | none ahead |
| Menarini Group | 20 open or running | phase 2since Feb 10, 2012 | Feb 10, 2012 | none ahead |
| Amit Malhotra, MD | 10 open or running | phase 4since Jan 26, 2017 | Jan 26, 2017 | none ahead |
| Haisco Pharmaceutical Group | 10 open or running | phase 1since Jun 27, 2025 | Jun 27, 2025 | none ahead |
| Novartis | 10 open or running | phase 2since Mar 21, 2012 | Mar 21, 2012 | none ahead |
| OBS Pakistan | 10 open or running | phase 4since Mar 15, 2018 | Mar 15, 2018 | none ahead |
| TSH Biopharm | 10 open or running | no phasesince Jan 7, 2018 | Jan 7, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Sep 8, 2004.
- Nov 11, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01472185 · 465 enrolled · United States, Czech Republic, Hungary and more
- Dec 15, 2011Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01494987 · 431 enrolled · United States, Czech Republic, Hungary and more
- Jan 18, 2012Phase 2 study in Atrial FibrillationGilead Sciences · NCT01522651 · 134 enrolled · United States, Germany, Israel and more
- Feb 10, 2012Menarini Group's first study: phase 2 study in Atrial FibrillationNew to Menarini GroupMenarini Group · NCT01534962 · 241 enrolled · Germany, Italy, Spain and more
- Feb 14, 20122 phase 1 studies in Diabetes Mellitus, Type 2Gilead Sciences · NCT01546597, NCT01546558
- Mar 13, 2012Phase 3 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01555164 · 442 enrolled · United States, Canada, Czech Republic and more
- Mar 21, 2012Novartis's first study: phase 2 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT01562041 · 14 enrolled · United States
- Jul 26, 2012Phase 1 study in Renal InsufficiencyGilead Sciences · NCT01675973 · 4 enrolled · United States
- Apr 17, 2013Phase 1 study in Diabetes Mellitus, Type 2Gilead Sciences · NCT01843127 · 24 enrolled · United States
- Apr 29, 2016Phase 1 study in Healthy Male IndividualsMenarini Group · NCT02817932 · 120 enrolled · Korea, Republic of
- Jan 26, 2017Amit Malhotra, MD's first study: phase 4 study in Angina PectorisNew to Amit Malhotra, MDAmit Malhotra, MD · NCT03044964 · 40 enrolled · United States
- Jan 7, 2018TSH Biopharm's first study: no phase study in Angina PectorisNew to TSH BiopharmTSH Biopharm · NCT03401502 · 20 enrolled · Taiwan
- Mar 15, 2018OBS Pakistan's first study: phase 4 study in Angina, StableNew to OBS PakistanOBS Pakistan · NCT03486561 · 2,000 enrolled
- Jun 27, 2025Haisco Pharmaceutical Group's first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07054255 · 72 enrolled · China
TargetBeta
“Sodium channel protein type V alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
| rufinamiderule | Eisai | phase 3 | 7 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07054255Healthy · China | 1 | Completed | Haisco Pharmaceutical Group | Nov 9, 2020 | 72 |
| NCT03486561Angina, Stable | 4 | UNKNOWN | OBS Pakistan | Sep 30, 2018 | 2,000 |
| NCT03401502Angina Pectoris · Taiwan | – | Completed | TSH Biopharm | Mar 30, 2019 | 20 |
| NCT03044964Angina Pectoris · United States | 4 | UNKNOWN | Amit Malhotra, MD | Oct 2017 | 40 |
| NCT02817932Healthy Male Individuals · Korea, Republic of | 1 | UNKNOWN | Menarini Group | Jul 2016 | 120 |
| NCT01843127Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Sep 2013 | 24 |
| NCT01675973Renal Insufficiency · United States | 1 | Terminated | Gilead Sciences | Aug 2012 | 4 |
| NCT01562041Cardiovascular Diseases · United States | 2 | Terminated | Novartis | Jan 2, 2014 | 14 |
| NCT01555164Diabetes Mellitus, Type 2 · United States, Canada, Czech Republic and more | 3 | Completed | Gilead Sciences | Sep 2013 | 442 |
| NCT01546558Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Mar 2012 | 25 |
| NCT01546597Diabetes Mellitus, Type 2 · United States | 1 | Completed | Gilead Sciences | Mar 2012 | 24 |
| NCT01534962Atrial Fibrillation · Germany, Italy, Spain and more | 2 | Completed | Menarini Group | Oct 2013 | 241 |
| NCT01522651Atrial Fibrillation · United States, Germany, Israel and more | 2 | Completed | Gilead Sciences | Mar 10, 2014 | 134 |
| NCT01494987Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Gilead Sciences | Aug 2013 | 431 |
| NCT01472185Diabetes Mellitus, Type 2 · United States, Czech Republic, Hungary and more | 3 | Completed | Gilead Sciences | Oct 2013 | 465 |
| NCT01442038Coronary Artery Disease · United States, Austria, Belgium and more | 3 | Completed | Gilead Sciences | Feb 2015 | 2,651 |
| NCT01425359Angina Pectoris · United States, Belarus, Bulgaria and more | 4 | Completed | Gilead Sciences | Oct 2012 | 949 |
| NCT01334203Angina Pectoris | 4 | Withdrawn | Gilead Sciences | Oct 2012 | 0 |
| NCT01221272Myocardial Ischemia · United States, Canada, Czech Republic and more | 4 | Completed | Gilead Sciences | Sep 2012 | 81 |
| NCT01163721Diabetes Mellitus, Type 2 · United States | 2 | Completed | Gilead Sciences | Nov 2010 | 80 |
| NCT01163734Heart Failure, Diastolic · Germany | 2 | Completed | Gilead Sciences | Feb 2011 | 20 |
| NCT00832572Coronary Artery Disease · United States | 4 | Terminated | Gilead Sciences | Jun 2009 | 5 |
| NCT00644332Chronic Angina · United States | 4 | Completed | Gilead Sciences | Jan 2011 | 172 |
| NCT00099788Myocardial Ischemia · United States | 3 | Completed | Gilead Sciences | Feb 2007 | 6,560 |
| NCT00091429Angina Pectoris | 3 | Completed | Gilead Sciences | Feb 2005 | 500 |
How it is read
Names in the registry
- “Ranolazine”, 24 entries
- “Test formulation (Ranolazine extended-release tablets)”, 1 entry
- “Reference formulation (Ranolazine extended-release tablets)”, 1 entry
- “Ranolazine 500 mg”, 1 entry
- “Ranolazine plus Metoprolol Combination”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 7 studies
- Angina Pectoris, 5 studies
- Atrial Fibrillation, 3 studies
- Coronary Artery Disease, 2 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.